Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Zydelig save search
Endeavour Silver Surpasses Upper Range of Production Guidance by Delivering 9.0 Million Silver Equivalent Ounces in 2022
Published: 2023-01-10 (Crawled : 12:00) - globenewswire.com
EXK | News | $2.56 -1.92% 0.0% 5M
|
Non-Energy Minerals
|
| O: 0.88%
H: 3.8%
C: 3.22%
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Published: 2022-12-21 (Crawled : 12:00) - ir.zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -3.07%
H: 7.62%
C: 5.16%
pharmaceuticals trial update
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
Published: 2022-11-28 (Crawled : 13:00) - globenewswire.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 7.1%
H: 0.0%
C: -0.62%
pharmaceuticals publication study
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-11-15 (Crawled : 13:00) - ir.zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -1.83%
H: 5.66%
C: 3.53%
pharmaceuticals designation drug granted
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in inno...
Published: 2022-06-22 (Crawled : 10:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 2.73%
H: 6.19%
C: 1.77%
trial positive results zygel topline
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-06-22 (Crawled : 01:00) - globenewswire.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 2.73%
H: 6.19%
C: 1.77%
trial positive results zygel topline phase 2
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Published: 2022-06-03 (Crawled : 17:00) - globenewswire.com
ESPR | $1.9 -2.56% -2.63% 4.5M
|
Health Technology
|
| O: -3.02%
H: 6.97%
C: 6.97%
risk
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
Published: 2022-05-11 (Crawled : 18:00) - globenewswire.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 4.59%
H: 0.88%
C: -16.66%
research children international zygel
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
Published: 2022-05-02 (Crawled : 12:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.71%
H: 3.55%
C: 3.55%
children zygel
TWC Enterprises Limited Announces 2021 Year End Results and Eligible Cash Dividend
Published: 2022-03-10 (Crawled : 01:00) - globenewswire.com
CUKPF 3 d | $12.5 -52.04% 750
|
Consumer Services
| Email alert
Add to watchlist
ces results
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X SyndromeProvides 10-year market exclusivity in EU upon regulatory approval
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
als europe drug granted approval drug designation orphan drug grant designation zygel
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Published: 2022-02-28 (Crawled : 21:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.91%
H: 3.38%
C: -2.7%
als europe drug granted drug designation orphan drug grant syndros designation zygel
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion SyndromeTopline data from Phase 2 INSPIRE trial expected mid-year 2022
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial topline enroll zygel
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-02-28 (Crawled : 13:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial syndros enroll zygel
JCP&L Proposal Supports New Jersey Clean Energy Plan by Delivering Wind Power to Customers with Minimal Community Impacts
Published: 2021-09-28 (Crawled : 21:00) - prnewswire.com
FE | $38.21 0.11% 0.0% 2.4M
|
Utilities
|
| O: 0.05%
H: 0.93%
C: -0.41%
energy liver
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Published: 2021-09-13 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 1.9%
C: -0.45%
phase 3 trial syndros zygel
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
Published: 2021-09-09 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 7.64%
C: 5.32%
children conference zygel lsd
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open
Published: 2021-09-07 (Crawled : 11:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -1.11%
H: 3.14%
C: 0.0%
phase 2 results children zygel
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
Published: 2021-05-05 (Crawled : 21:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 1.61%
H: 1.13%
C: -9.48%
phase 3 trial syndros designation zygel
TransGlobe Energy Corporation Announces Its US Listing Transfer to Nasdaq Capital Market and Eligibility for an Additional 180-Day Grace Period to Regain Compliance With the Minimum Bid Price Requirement
Published: 2020-12-30 (Crawled : 22:01) - globenewswire.com
TGA | $3.72 2.15%
|
Energy Minerals
|
| O: 10.22%
H: 1.65%
C: 0.15%
energy trace
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.